WASHINGTON — President Donald Trump announced Monday that nine additional pharmaceutical companies have agreed to participate in his administration’s effort to reduce prescription drug prices in the United States.
The agreements are part of the administration’s Most Favored Nation initiative, which seeks to align certain U.S. medication prices with lower prices available in other countries. The new commitments bring the total number of participating manufacturers to 26, representing approximately 89% of the country’s branded prescription drug market, according to a White House fact sheet.
The nine companies joining the initiative are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB.
The White House said the agreements cover medications used to treat several chronic, rare and costly conditions, including Parkinson’s disease, hemophilia, glaucoma, macular degeneration, liver disease, skin disorders and certain forms of cancer.
State Medicaid programs will also receive access to the negotiated prices for products manufactured by the nine companies. However, the extent to which the agreements will reduce individual patients’ out-of-pocket expenses remains unclear because Medicaid already receives federally required drug discounts.
Administration officials estimate that the broader pricing initiative could save Americans more than $600 billion over the next decade. That figure is a projection and will depend on how the agreements are implemented and how broadly the reduced prices are made available.
As part of the arrangements, the nine manufacturers have collectively committed to investing at least $19.6 billion in U.S. pharmaceutical production. Several companies will also contribute ingredients used to manufacture certain medications to the Strategic Active Pharmaceutical Ingredients Reserve, an effort intended to strengthen the country’s emergency drug supply and reduce dependence on foreign sources.
The administration has previously reached similar agreements with 17 pharmaceutical companies, including Pfizer, Eli Lilly and Novo Nordisk.
Some participating manufacturers are also offering discounted medications through TrumpRx, the administration’s prescription-drug purchasing platform. The White House reports that patients have saved more than $700 million through the service since its launch in February.
Trump initially revived the Most Favored Nation policy through an executive order signed in May 2025. The administration is continuing to promote the initiative as part of its broader healthcare affordability agenda.
